Provision Language
<p class=”p2“><span style=”text–decoration: underline;”><b>16. Preparation for Outbreaks b>span>p>
<p class=”p3“><i>[This Clause 16 explains that Awardee may be requested to undertake additional Product–related work at CEPI’s expense, consistent with the provisions of Equitable Access. If Awardee is unable or unavailable to do so, CEPI would prefer that Awardee designate a trusted collaborator to complete this work. The definition of “<a href=”#kt“>Outbreaka>” reflects the WHO definition and may be triggered by WHO or declarations by governments in an affected area.] i>p>
<p><strong>16.4 Trusted Collaborator.strong> At the time that Awardee submits a Phase 2 study report to CEPI (or at any earlier time), Awardee will propose a third party, for example, a Sub–Awardee, as a preferred alternative to itself (“<em><strong>Trusted Collaboratorstrong>em>”), that is capable of performing the work and would be prepared to undertake activities pursuant to Clauses 16.2 or 16.3 in the event that Awardee declines CEPI’s request to do so, or if Awardee and CEPI do not reach agreement on a new Work Package. Alternatively, CEPI may propose a Trusted Collaborator to Awardee. Neither Party may unreasonably decline to accept the designation of a proposed Trusted Collaborator.p>
<p><strong>16.5 Technology Transfer.strong> As described in the IPDP, or otherwise upon designation of a Trusted Collaborator pursuant to Clause 16.4, Awardee will promptly and diligently provide all necessary guidance, information, materials and assistance reasonably required by the Trusted Collaborator to accomplish the activities that may be requested by CEPI under Clauses <span style=”text–decoration: underline;”><a href=”https://ghiaa.org/provision_document/cepi–cfp3i–template–funding–agreement–5/” target=”_blank” rel=”noopener“>16.2 or 16.3a>span> (“<em><strong>Technology Transferstrong>em>”) at CEPI’s reasonable cost.p>
